Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure.
CONCLUSIONS: SGLT2 inhibitors have a protective effect in Dox-induced HF in mice. This implied that SGLT2 inhibitor therapy could be a good treatment strategy even in HF patients without diabetes.
PMID: 31456369 [PubMed - as supplied by publisher]
Source: Korean Circulation Journal - Category: Cardiology Tags: Korean Circ J Source Type: research
More News: Cardiology | Cardiomyopathy | Cardiovascular | Diabetes | Diets | Empagliflozin | Endocrinology | Heart | Heart Failure | Jardiance | Nutrition | SGLT2 Inhibitors | Sodium | Study | Toxicology